The first recorded case of vulvar cancer that occurred alongside an infection with the Fusobacterium necrophorum bacteria was described in a recent case report…
News
Researchers in Belgium have developed an atlas to mark changes in distinct types of immune cells during multiple myeloma’s  progression. Their work, in…
The U.S. Food and Drug Administration (FDA) has approved an oral liquid formulation of imatinib, now called Imkeldi, to treat specific forms of…
PANCREATIC CANCER
Somatostatin may be safe option for certain tumors during pregnancy
For about one-third of women with a neuroendocrine tumor — or an abnormal mass of tissue that forms from hormone-releasing cells, such as those in…
GYNECOLOGICAL CANCER
Vitamin D seen to prevent ovarian cancer’s onset in disease models
Vitamin D may help to prevent the development of ovarian cancers, according to new studies in mice and cell disease models. “These data strongly…
The U.S. Food and Drug Administration (FDA) will review GSK’s request to approve Blenrep (belantamab mafodotin) as part of a combination treatment for adults…
The U.S. Food and Drug Administration (FDA) has approved revumenib, now called Revuforj, as an oral therapy for children and adults, ages 1 year and…
PANCREATIC CANCER
Treatment before surgery slows PDAC disease progression: Study
Neoadjuvant therapy, or treatment to shrink tumors before the surgery to remove them, delayed disease progression, reduced recurrence, and extended survival in people with pancreatic…
U.S. scientists have discovered that pediatric low-grade gliomas — a type of brain cancer that can occur in children — are generally softer than normal…
GYNECOLOGICAL CANCER
Elahere approved in EU as treatment for ovarian cancer
AbbVie’s Elahere (mirvetuximab soravtansine) has been approved in the European Union to treat adults with advanced ovarian, fallopian tube, or primary peritoneal cancer whose…
Recent Posts
- My husband and I aren’t just each other’s caregivers; we’re care partners
- Under-the-skin myeloma therapy shows strong responses in Phase 2 trial
- Trial finds treatment eases PV symptoms despite missing main goal
- The quiet courage of taking a short break as a caregiver
- EU clears Tecvayli as solo option when myeloma returns after first treatment